AstraZeneca and Daiichi Sankyo Score Breakthrough Lung Cancer Approval with Datroway

Precision medicine just landed a direct hit on one of cancer’s most challenging targets. AstraZenecaAZN

and partner Daiichi Sankyo scored a regulatory victory Tuesday when the FDA greenlit their precision drug Datroway for treating advanced non-small cell lung cancer. This approval marks the first time this class of antibody-drug conjugate has received clearance for lung cancer in the world’s largest pharmaceutical market, expanding options for patients whose tumors have developed resistance to previous therapies.

• Unlike traditional chemotherapy that attacks both healthy and cancerous cells, Datroway specifically targets the TROP2 protein found on tumor surfaces while sparing normal tissue.
• AstraZeneca will pay Daiichi Sankyo $45M as a milestone payment following the US approval, part of their broader $6B collaboration deal struck in 2020.

The prognosis ahead: So far, clinical data has shown that the treatment achieved a 45% response rate in previously treated patients, with responses lasting a median of 6.5 months. Companies are already evaluating Datroway in combination with other therapies across multiple lung cancer settings to expand its reach to earlier-stage patients who could benefit from this precision approach. With nearly 2.5M lung cancer cases diagnosed globally in 2022, this breakthrough offers fresh hope for patients facing limited later-line treatment options.